A poster session was presented that indicated an indirect comparison of TAK-788 vs. real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions. The intervention TAK 788 is produced by Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. TAK 788 is a small molecule, and in the clinical trial study - nct02716116, a total of 99 patients were enrolled.